US Product Hopping Legislation Could Offer $3bn In Savings
The Bill Would Allow FTC To Seek Remedies And Limit Patents Asserted Against Biosimilars
In the ongoing fight for fair market competition and improved medication access, the US Congressional Budget Office calculated $3bn in savings from a bill that would prevent originators from product hopping.
